Search results for "AGENT"

showing 10 items of 8904 documents

Impact of Age, Multimorbidity and Frailty on the Prescription of Preventive Antiplatelet Therapy in Older Population

2020

Platelet aggregation inhibitors (PAI) have widely proven their efficiency for the prevention of ischemic cardiovascular events. We aimed to describe PAI prescription in an elderly multimorbid population and to determine the factors that influence their prescription, including the impact of age, comorbidities and frailty, evaluated through a comprehensive geriatric assessment. This cross-sectional study included all patients admitted to the acute geriatric department of a university hospital from November 2016 to January 2017. We included 304 consecutive hospitalized patients aged 88.7 &plusmn

medicine.medical_specialtymultimorbidityHealth Toxicology and MutagenesisFrail ElderlyPopulationlcsh:MedicineunderuseDiseasefrailty030204 cardiovascular system & hematologyoveruseelderlyArticle03 medical and health sciences0302 clinical medicineInternal medicineMedicineHumansMedical history030212 general & internal medicineMedical prescriptionPractice Patterns Physicians'educationplatelet aggregation inhibitorsGeriatric AssessmentAgedAged 80 and overeducation.field_of_studyMini–Mental State Examinationmedicine.diagnostic_test[SDV.MHEP.GEG] Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontologybusiness.industry[SDV.MHEP.GEG]Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontologylcsh:RPublic Health Environmental and Occupational HealthOdds ratiocomprehensive geriatric assessmentConfidence intervalCross-Sectional StudiesagePlatelet aggregation inhibitorFemaleantiplatelet agentsbusinessInternational Journal of Environmental Research and Public Health
researchProduct

Hormonal Contraceptive Use Does Not Affect Strength, Endurance, or Body Composition Adaptations to Combined Strength and Endurance Training in Women

2021

Myllyaho, MM, Ihalainen, JK, Hackney, AC, Valtonen, M, Nummela, A, Vaara, E, Häkkinen, K, Kyröläinen, H, and Taipale, RS. Hormonal contraceptive use does not affect strength, endurance, or body composition adaptations to combined strength and endurance training in women. J Strength Cond Res 35(2): 449-457, 2021-This study examined the effects of a 10-week period of high-intensity combined strength and endurance training on strength, endurance, body composition, and serum hormone concentrations in physically active women using hormonal contraceptives (HCs, n = 9) compared with those who had never used hormonal contraceptives (NHCs, n = 9). Training consisted of 2 strength training sessions a…

medicine.medical_specialtynaisetactive womenPhysical Therapy Sports Therapy and Rehabilitation030204 cardiovascular system & hematologyAffect (psychology)high intensity training03 medical and health sciences0302 clinical medicineContraceptive AgentsEndurance trainingHumansMedicineOrthopedics and Sports MedicineMuscle Strengthehkäisymenetelmäthormonaaliset vaikutuksetkehonkoostumussuorituskykybusiness.industryResistance Training030229 sport sciencesGeneral Medicinephysical performanceEndurance TrainingContraceptive useBody CompositionPhysical EndurancePhysical therapyFemalebusinessHormonefysiologiset vaikutuksetlihasvoima
researchProduct

Reduced-Dose Intravenous Thrombolysis for Acute Intermediate–High-risk Pulmonary Embolism: Rationale and Design of the Pulmonary Embolism Internation…

2021

Intermediate-high-risk pulmonary embolism (PE) is characterized by right ventricular (RV) dysfunction and elevated circulating cardiac troponin levels despite apparent hemodynamic stability at presentation. In these patients, full-dose systemic thrombolysis reduced the risk of hemodynamic decompensation or death but increased the risk of life-threatening bleeding. Reduced-dose thrombolysis may be capable of improving safety while maintaining reperfusion efficacy. The Pulmonary Embolism International THrOmbolysis (PEITHO)-3 study (ClinicalTrials.gov Identifier: NCT04430569) is a randomized, placebo-controlled, double-blind, multicenter, multinational trial with long-term follow-up. We will c…

medicine.medical_specialtypulmonary embolismVentricular Dysfunction Rightmedicine.medical_treatment2720 HematologyHemodynamicsHemorrhage610 Medicine & health030204 cardiovascular system & hematologyintermediate-high-risk; prognosis; pulmonary embolism; randomized trial; reduced-dose thrombolysis03 medical and health sciences0302 clinical medicineFibrinolytic AgentsInternal medicinemedicinerandomized trialHumansThrombolytic TherapyDecompensationStrokeHeparinbusiness.industry10031 Clinic for AngiologyHematologyThrombolysismedicine.diseasereduced-dose thrombolysis3. Good healthPulmonary embolismRegimenTreatment OutcomeBlood pressure030228 respiratory systemTissue Plasminogen ActivatorHeart failureAcute DiseaseCardiologyprognosisintermediate-high-riskbusiness
researchProduct

Are biological drugs effective and safe in older severe asthmatics?

2019

Introduction: The treatment of asthma in older ages follows the recommendations of international guidelines for the management of asthma in younger ages, although older age has always represented an exclusion criterion for eligibility to pharmacological trials. This poses a clinical challenge when deciding whether elderly severe asthmatics are candidates for biological drugs. Areas covered: The current article has a narrative structure to review the current literature on efficacy and safety of novel pharmacological drugs against immunoglobulins and interleukins that mediate and orchestrate the main inflammatory pathways in severe asthma, in order to explore whether older subjects (i.e. >…

medicine.medical_specialtypulmonary eosinophilia/drug therapyeducationImmunoglobulinsmonoclonal030204 cardiovascular system & hematologySettore MED/10 - Malattie Dell'Apparato RespiratorioAnti-asthmatic AgentSeverity of Illness IndexBiological drugs03 medical and health sciences0302 clinical medicineimmune system diseasesInternal medicineSeverity of illnessImmunoglobulinHumansMedicineAnti-Asthmatic AgentPharmacology (medical)Age FactorAnti-Asthmatic AgentsAsthmaAgedRandomized Controlled Trials as TopicBiological ProductsAsthma/drug therapybiologyhumanizedbusiness.industryInterleukinsAge FactorsGeneral MedicineInterleukinmedicine.diseaseAsthmarespiratory tract diseasesantibodie030220 oncology & carcinogenesisMonoclonalPractice Guidelines as Topicbiology.proteinBiological Productanti-asthmatic agents/pharmacologyAntibodybusinessHuman
researchProduct

Could isotretinoin be a protective agent against COVID-19?: A dermatologist perspective.

2021

Being a "trending" unique treatment for moderate-to-severe acne, isotretinoin (13-cis retinoic acid) (ISO) is currently considered by experts the first line treatment even for mild acne, unless there is an absolute contraindication. ISO was identified, among other retinoids, to inhibit SARS-CoV-2 replication in Vero E6 cells. Shoemark et al.1.

medicine.medical_specialtyskinCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Retinoic acidDermatologyProtective Agents030207 dermatology & venereal diseases03 medical and health scienceschemistry.chemical_compound0302 clinical medicineCOVID‐19Acne VulgarismedicineHumansskin and connective tissue diseasesLetters to the EditorIsotretinoinContraindicationAcnebusiness.industrySARS-CoV-2COVID-19isotretinoinmedicine.diseaseDermatologyFirst line treatmentchemistry030220 oncology & carcinogenesisVero cellbusinessmedicine.drugDermatologistsJournal of cosmetic dermatology
researchProduct

<p>Clinical Evaluation of Everolimus in the Treatment of Neuroendocrine Tumors of the Lung: Patient Selection and Special Considerations. A Sys…

2020

Abstract Neuroendocrine tumors (NETs) of the lung are well-differentiated neuroendocrine neoplasms (NENs) with a heterogeneous clinical behaviour. Unlike gastroenteropancreatic NENs where therapeutic armamentarium clearly increased over the last decade, everolimus represented the only clinical practical innovation for lung NET patients over the last years. Therefore, for lung NETs, a multidisciplinary discussion within a dedicated team remains critical for an adequate decision-making. Although the main regulatory authorities considered the everolimus-related evidence is enough to approve the drug in advanced lung NETs, several clinical features deserve to be discussed. In this review, we sy…

medicine.medical_specialtytargeted agentsEverolimusLungbusiness.industryContext (language use)Reviewrespiratory systemNeuroendocrine tumorseverolimusmedicine.diseaseatypical carcinoidClinical Practicelung NETtypical carcinoidmedicine.anatomical_structureOncologymammalian target of rapamycin (mTOR) inhibitormedicineTypical carcinoidIntensive care medicinebusinessAtypical carcinoidClinical evaluationmedicine.drugLung Cancer: Targets and Therapy
researchProduct

A Non-Interventional Study of Tiotropium/Olodaterol versus Any Triple Combination Therapy for Chronic Obstructive Pulmonary Disease: The EVELUT® Stud…

2020

Roland Buhl,1 Michael Dreher,2 Stephanie Korn,1 Christian Taube,3 Christian Stock,4 Christoph M Zehendner,5 Anke Kondla,5 Claus F Vogelmeier6 1Pulmonary Department, Johannes Gutenberg University Mainz, Mainz, Germany; 2Clinic of Cardiology, Pneumology, Angiology and Internal Medicine Intensive Care, University Hospital RWTH Aachen, Aachen, Germany; 3Clinic for Pneumonology, University Medicine Essen – Ruhrlandklinik, Essen, Germany; 4Biostatistics + Data Sciences Corp, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany; 5HP Country Medical Affairs, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany; 6Department of Pneumology,…

medicine.medical_specialtytiotropium/olodaterolMedizinMuscarinic AntagonistsInternational Journal of Chronic Obstructive Pulmonary Disease03 medical and health scienceschemistry.chemical_compoundStudy ProtocolPulmonary Disease Chronic Obstructive0302 clinical medicineMaintenance therapySpiolto® Respimat®Internal medicineAdministration Inhalationmedicinemedia_common.cataloged_instanceCOPDHumansMulticenter Studies as Topic030212 general & internal medicineProspective StudiesEuropean unionTiotropium BromideAdrenergic beta-2 Receptor Agonistsmedia_commonCOPDbiologybusiness.industryInhalerOlodaterolGeneral MedicineLamamedicine.diseasebiology.organism_classificationLAMA/LABA/ICShumanitiesObstructive lung diseaseBenzoxazinesBronchodilator AgentsRegimen030228 respiratory systemchemistrytriple therapyDrug Therapy Combinationbusinesshormones hormone substitutes and hormone antagonistsInternational Journal of Chronic Obstructive Pulmonary Disease
researchProduct

Does anti-inflammatory drugs modify the severe odontogenic infection prognosis? A 10-year’s experience

2020

Background Numerous biochemical datas support the noxious role of anti-inflammatory drugs on immune response. Those observations are often put forward for unfavorable evolution of odontogenic infection but has never been really proven in clinic. The aim of this study is to try to clarify this role based on the collection of the clinical course of odontogenic infections over a 10-year analysis period. Material and Methods The investigators implemented a prospective observational study. The sample was composed of patients managed between January 2004 and December 2014 for severe odontogenic infection based on three criteria: hospital admission, intravenous antibiotic therapy, tooth extraction…

medicine.medical_specialtytumorErythemamedicine.drug_classMESH: Pharmaceutical PreparationsPopulationAnti-Inflammatory AgentsPaincarcinomaMESH: Prognosislip03 medical and health sciences0302 clinical medicine[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesInternal medicinemedicineHumanseducationGeneral DentistryUNESCO:CIENCIAS MÉDICASOdontogenic infectioncystUnivariate analysiseducation.field_of_studyMESH: Humansbusiness.industryResearchAnti-Inflammatory Agents Non-Steroidal030206 dentistrymedicine.diseasePrognosisMESH: Anti-Inflammatory Agents Non-SteroidalOtorhinolaryngologyPharmaceutical PreparationsMESH: Anti-Inflammatory AgentsPropensity score matching[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseasesCorticosteroidSurgeryObservational studyMESH: Painmedicine.symptomOral SurgerybusinessOdynophagianeoplasm
researchProduct

Cohort profile: Thrombolysis in Ischemic Stroke Patients (TRISP): a multicentre research collaboration

2018

PurposeThe ThRombolysis in Ischemic Stroke Patients (TRISP) collaboration aims to address clinically relevant questions about safety and outcomes of intravenous thrombolysis (IVT) and endovascular thrombectomy. The findings can provide observational information on treatment of patients derived from everyday clinical practice.ParticipantsTRISP is an open, investigator-driven collaborative research initiative of European stroke centres with expertise in treatment with revascularisation therapies and maintenance of hospital-based registries. All participating centres made a commitment to prospectively collect data on consecutive patients with stroke treated with IVT using standardised definiti…

medicine.medical_treatment2700 General Medicineregistry030204 cardiovascular system & hematologyRECOMMENDATIONS3124 Neurology and psychiatryBrain Ischemia0302 clinical medicineMedicineProspective StudiesRegistries10064 Neuroscience Center ZurichProspective cohort studyIntersectoral CollaborationThrombectomyRISKEndovascular ProceduresThrombolysisGeneral Medicine3. Good healthStrokeCohortrevascularizationAdministration IntravenousINTRAVENOUS THROMBOLYSISthrombolysismedicine.medical_specialtyMEDLINE610 Medicine & healthRevascularizationfunctional outcome; registry; revascularization; stroke; thrombectomy; thrombolysisCLASSIFICATIONfunctional outcomePOOLED ANALYSIS03 medical and health sciencesALTEPLASEFibrinolytic AgentsHumansMETAANALYSISbusiness.industryStatin treatment10040 Clinic for NeurologyIV THROMBOLYSISSYMPTOMATIC INTRACEREBRAL HEMORRHAGE3121 General medicine internal medicine and other clinical medicineIschemic strokeEmergency medicine570 Life sciences; biologyObservational studybusiness030217 neurology & neurosurgeryBMJ open
researchProduct

Inhibition of the NF-κB Signaling Pathway Mediates the Anti-inflammatory Effects of Petrosaspongiolide M

2003

Petrosaspongiolide M (PT) is a potent secretory phospholipase A(2) inhibitor and anti-inflammatory agent. This marine metabolite reduced the production of nitrite, prostaglandin E(2), and tumor necrosis factor-alpha in the mouse air pouch injected with zymosan. These effects were also observed in mouse peritoneal macrophages stimulated with zymosan. Inhibition of these inflammatory mediators was related to reductions in inducible nitric oxide synthase, cyclo-oxygenase-2, and tumor necrosis factor-alpha expression. Since nuclear factor-kappaB (NF-kappaB) appears to play a central role in the transcriptional regulation of these proteins by macrophages, we investigated the effects of PT on thi…

medicine.medical_treatmentAnti-Inflammatory AgentsNitric Oxide Synthase Type IIBiochemistryDinoprostoneMicechemistry.chemical_compoundPhospholipase A2NF-KappaB Inhibitor alphaCell MovementmedicineAnimalsRNA MessengerOleanolic AcidPhosphorylationNitritesPharmacologybiologyTumor Necrosis Factor-alphaZymosanNF-kappa BZymosanBiological TransportNF-κBDNACell biologyIsoenzymesNitric oxide synthaseIκBαCytokinechemistryBiochemistryCyclooxygenase 2Prostaglandin-Endoperoxide SynthasesModels AnimalMacrophages Peritonealbiology.proteinCytokinesI-kappa B ProteinsTumor necrosis factor alphaNitric Oxide SynthaseSignal TransductionProstaglandin E
researchProduct